Equities analysts forecast that Nabriva Therapeutics PLC – (NASDAQ:NBRV) will report sales of $2.60 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Nabriva Therapeutics’ earnings, with the lowest sales estimate coming in at $600,000.00 and the highest estimate coming in at $7.07 million. Nabriva Therapeutics posted sales of $970,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 168%. The firm is expected to issue its next earnings results on Thursday, November 8th.
On average, analysts expect that Nabriva Therapeutics will report full year sales of $11.57 million for the current year, with estimates ranging from $9.45 million to $16.32 million. For the next fiscal year, analysts anticipate that the business will report sales of $16.49 million, with estimates ranging from $7.00 million to $29.77 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.04. Nabriva Therapeutics had a negative return on equity of 77.40% and a negative net margin of 642.38%. The business had revenue of $0.85 million for the quarter, compared to the consensus estimate of $1.16 million.
NASDAQ NBRV opened at $2.70 on Friday. Nabriva Therapeutics has a twelve month low of $2.33 and a twelve month high of $6.94. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -1.12 and a beta of 1.46.
In other Nabriva Therapeutics news, Director Daniel D. Burgess bought 36,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 31st. The shares were bought at an average cost of $2.75 per share, with a total value of $99,000.00. Following the completion of the purchase, the director now directly owns 36,000 shares of the company’s stock, valued at $99,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.79% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in shares of Nabriva Therapeutics by 163.9% in the first quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 15,501 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Nabriva Therapeutics by 4,353.6% in the second quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 54,159 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Nabriva Therapeutics by 173.2% in the first quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 70,917 shares during the last quarter. Wedbush Securities Inc. bought a new stake in shares of Nabriva Therapeutics in the second quarter worth about $371,000. Finally, Prosight Management LP grew its stake in shares of Nabriva Therapeutics by 73.6% in the second quarter. Prosight Management LP now owns 421,414 shares of the biotechnology company’s stock worth $1,467,000 after purchasing an additional 178,725 shares during the last quarter. 52.53% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Further Reading: Call Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.